<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36321729</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles.</ArticleTitle><Pagination><StartPage>208</StartPage><EndPage>216</EndPage><MedlinePgn>208-216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27744</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Body mass index (BMI) is linked to amyotrophic lateral sclerosis (ALS) risk and prognosis, but additional research is needed. The aim of this study was to identify whether and when historical changes in BMI occurred in ALS participants, how these longer term trajectories associated with survival, and whether metabolomic profiles provided insight into potential mechanisms.</AbstractText><AbstractText Label="METHODS">ALS and control participants self-reported body height and weight 10 (reference) and 5&#x2009;years earlier, and at study entry (diagnosis for ALS participants). Generalized estimating equations evaluated differences in BMI trajectories between cases and controls. ALS survival was evaluated by BMI trajectory group using accelerated failure time models. BMI trajectories and survival associations were explored using published metabolomic profiling and correlation networks.</AbstractText><AbstractText Label="RESULTS">Ten-year BMI trends differed between ALS and controls, with BMI loss in the 5&#x2009;years before diagnosis despite BMI gains 10 to 5&#x2009;years beforehand in both groups. An overall 10-year drop in BMI associated with a 27.1% decrease in ALS survival (P&#xa0;=&#x2009;.010). Metabolomic networks in ALS participants showed dysregulation in sphingomyelin, bile acid, and plasmalogen subpathways.</AbstractText><AbstractText Label="DISCUSSION">ALS participants lost weight in the 5-year period before enrollment. BMI trajectories had three distinct groups and the group with significant weight loss in the past 10&#x2009;years had the worst survival. Participants with a high BMI and increase in weight in the 10&#x2009;years before symptom onset also had shorter survival. Certain metabolomics profiles were associated with the BMI trajectories. Replicating these findings in prospective cohorts is warranted.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5285-3038</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Gayatri</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8100-0832</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habra</LastName><ForeName>Hani</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4838-0105</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-5575-2494</Identifier><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karnovsky</LastName><ForeName>Alla</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7388-8520</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Bhramar</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0118-4561</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9162-2694</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01TS000289</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS127188</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>200-2013-56856</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Muscle Nerve. 2023 Mar;67(3):191-192</RefSource><PMID Version="1">36602891</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">body mass index</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement><b>Disclosure of Conflicts of Interest:</b> None of the authors have any conflict of interest relevant to this research activity to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36321729</ArticleId><ArticleId IdType="mid">NIHMS1847255</ArticleId><ArticleId IdType="pmc">PMC9957813</ArticleId><ArticleId IdType="doi">10.1002/mus.27744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. The Lancet Neurology. May 2022;21(5):480&#x2013;493. doi:10.1016/S1474-4422(21)00465-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology. May 2022;21(5):465&#x2013;479. doi:10.1016/S1474-4422(21)00414-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration. Aug 2019;20(5&#x2013;6):303&#x2013;309. doi:10.1080/21678421.2019.1587634</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. Jun 2019;90(6):666&#x2013;673. doi:10.1136/jnnp-2018-319611</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Rosenbohm A, Dupuis L, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. Oct 2017;32(10):901&#x2013;908. doi:10.1007/s10654-017-0318-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O, Meyer HE, Stigum H, Holmoy T. High BMI is associated with low ALS risk: A population-based study. Neurology. Jul 30 2019;93(5):e424&#x2013;e432. doi:10.1212/WNL.0000000000007861</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly &#xc9;J, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. Apr 2013;14(3):205&#x2013;11. doi:10.3109/21678421.2012.735240</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly EJ, Wang M, Adami HO, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration. Aug 2018;19(5&#x2013;6):396&#x2013;406. doi:10.1080/21678421.2018.1452944</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1452944</ArticleId><ArticleId IdType="pmc">PMC6423444</ArticleId><ArticleId IdType="pubmed">29658324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Beard JD, Umbach DM, et al. Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am J Epidemiol. Mar 1 2017;185(5):362&#x2013;371. doi:10.1093/aje/kww140</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww140</ArticleId><ArticleId IdType="pmc">PMC5860019</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. Feb 26 2013;80(9):829&#x2013;38. doi:10.1212/WNL.0b013e3182840689</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840689</ArticleId><ArticleId IdType="pmc">PMC3598455</ArticleId><ArticleId IdType="pubmed">23390184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ. Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neuro-degenerative diseases. 2016;16(5&#x2013;6):382&#x2013;97. doi:10.1159/000446502</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446502</ArticleId><ArticleId IdType="pubmed">27400276</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of neurology, neurosurgery, and psychiatry. Oct 2018;89(10):1016&#x2013;1023. doi:10.1136/jnnp-2017-317887</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology. Jan 2011;10(1):75&#x2013;82. doi:10.1016/S1474-4422(10)70224-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstrom H, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Annals of neurology. May 2017;81(5):718&#x2013;728. doi:10.1002/ana.24936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. Apr 28 2020;94(17):e1835&#x2013;e1844. doi:10.1212/WNL.0000000000009322</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Guo L, Leon Swisher C, et al. Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. Cell Metab. Feb 5 2019;29(2):488&#x2013;500.e2. doi:10.1016/j.cmet.2018.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.09.022</ArticleId><ArticleId IdType="pmc">PMC6370944</ArticleId><ArticleId IdType="pubmed">30318341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JE, Larson MG, Ghorbani A, et al. Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016;11(2):e0148361. doi:10.1371/journal.pone.0148361</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148361</ArticleId><ArticleId IdType="pmc">PMC4749349</ArticleId><ArticleId IdType="pubmed">26863521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus WE, Pieper CF, Huffman KM, et al. Association of Plasma Small-Molecule Intermediate Metabolites With Age and Body Mass Index Across Six Diverse Study Populations. J Gerontol A Biol Sci Med Sci. Nov 2016;71(11):1507&#x2013;1513. doi:10.1093/gerona/glw031</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw031</ArticleId><ArticleId IdType="pmc">PMC6279215</ArticleId><ArticleId IdType="pubmed">26984390</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry. Aug 2019;90(8):907&#x2013;912. doi:10.1136/jnnp-2018-319785</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319785</ArticleId><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Su FC, Goutman SA, Chernyak S, et al. Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA neurology. Jul 1 2016;73(7):803&#x2013;11. doi:10.1001/jamaneurol.2016.0594</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.0594</ArticleId><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Su FC, Callaghan BC, Goutman SA, Batterman SA, Feldman EL. Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan. PloS one. Jun 30 2014;9(6):e101186. doi:ARTN e101186 10.1371/journal.pone.0101186</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0101186</ArticleId><ArticleId IdType="pmc">PMC4076303</ArticleId><ArticleId IdType="pubmed">24979055</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Godwin C, Mukherjee B, Feldman EL, Batterman SA. Associations of self-reported occupational exposures and settings to ALS: a case-control study. Int Arch Occup Environ Health. Sep 2022;95(7):1567&#x2013;1586. doi:10.1007/s00420-022-01874-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00420-022-01874-4</ArticleId><ArticleId IdType="pmc">PMC9424174</ArticleId><ArticleId IdType="pubmed">35593931</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. Dec 2000;1(5):293&#x2013;9. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. Jul 1 1972;25(6):329&#x2013;43. doi:10.1016/0021-9681(72)90027-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(72)90027-6</ArticleId><ArticleId IdType="pubmed">4650929</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Guo K, et al. Untargeted metabolomics yields insight into ALS disease mechanisms. Journal of neurology, neurosurgery, and psychiatry. Dec 2020;91(12):1329&#x2013;1338. doi:10.1136/jnnp-2020-323611</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323611</ArticleId><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Guo K, Savelieff MG, et al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain : a journal of neurology. Jan 28 2022;doi:10.1093/brain/awac025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac025</ArticleId><ArticleId IdType="pmc">PMC9762943</ArticleId><ArticleId IdType="pubmed">35088843</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY, Zeger SL. Longitudinal Data-Analysis Using Generalized Linear-Models. Biometrika. Apr 1986;73(1):13&#x2013;22. doi:DOI 10.1093/biomet/73.1.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/73.1.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Halekoh U, H&#xf8;jsgaard S, Yan J. TheRPackagegeepackfor Generalized Estimating Equations. Journal of Statistical Software. 12/22 2006;15(2):1&#x2013;11. doi:10.18637/jss.v015.i02</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v015.i02</ArticleId></ArticleIdList></Reference><Reference><Citation>Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R Packages to Cluster Longitudinal Data. 2015. 2015-06-01 2015;65(4):34. doi:10.18637/jss.v065.i04</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v065.i04</ArticleId></ArticleIdList></Reference><Reference><Citation>Calinski T, Harabasz J. A dendrite method for cluster analysis. Communications in Statistics - Theory and Methods. 1974/01/01 1974;3(1):1&#x2013;27. doi:10.1080/03610927408827101</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610927408827101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gower JC. Some Distance Properties of Latent Root and Vector Methods Used in Multivariate Analysis. Biometrika. 1966;53(3/4):325&#x2013;&amp;. doi:DOI 10.1093/biomet/53.3-4.325</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/53.3-4.325</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S, Duren W, Evans CR, Burant CF, Michailidis G, Karnovsky A. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. Bioinformatics. May 15 2017;33(10):1545&#x2013;1553. doi:10.1093/bioinformatics/btx012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx012</ArticleId><ArticleId IdType="pmc">PMC5860222</ArticleId><ArticleId IdType="pubmed">28137712</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer GR, Wigginton J, Duren W, et al. Application of Differential Network Enrichment Analysis for Deciphering Metabolic Alterations. Metabolites. Nov 24 2020;10(12)doi:10.3390/metabo10120479</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo10120479</ArticleId><ArticleId IdType="pmc">PMC7761243</ArticleId><ArticleId IdType="pubmed">33255384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Karnovsky A, Afshinnia F, et al. Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics. Sep 15 2019;35(18):3441&#x2013;3452. doi:10.1093/bioinformatics/btz114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz114</ArticleId><ArticleId IdType="pmc">PMC6748777</ArticleId><ArticleId IdType="pubmed">30887029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancichinetti A, Fortunato S. Consensus clustering in complex networks. Sci Rep. 2012/03/27 2012;2(1):336. doi:10.1038/srep00336</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00336</ArticleId><ArticleId IdType="pmc">PMC3313482</ArticleId><ArticleId IdType="pubmed">22468223</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. A Note on the Group Lasso and a Sparse Group Lasso. arXiv:10010736. 01/05 2010;22</Citation></Reference><Reference><Citation>Huisman MH, Seelen M, van Doormaal PT, et al. Effect of Presymptomatic Body Mass Index and Consumption of Fat and Alcohol on Amyotrophic Lateral Sclerosis. JAMA neurology. Oct 2015;72(10):1155&#x2013;62. doi:10.1001/jamaneurol.2015.1584</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1584</ArticleId><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, van Veenhuijzen K, van der Spek RA, et al. Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. The Lancet Neurology. May 2021;20(5):373&#x2013;384. doi:10.1016/S1474-4422(21)00042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00042-9</ArticleId><ArticleId IdType="pubmed">33894192</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem MR, van Eijk RPA, van der Burgh HK, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. Aug 2020;91(8):867&#x2013;875. doi:10.1136/jnnp-2020-322909</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322909</ArticleId><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Kurihara M, Ogawa N, et al. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci Rep. Sep 9 2021;11(1):17943. doi:10.1038/s41598-021-97196-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-97196-5</ArticleId><ArticleId IdType="pmc">PMC8429558</ArticleId><ArticleId IdType="pubmed">34504168</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. Jan 2018;25(1):97&#x2013;104. doi:10.1111/ene.13468</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Zhang Z, O&#x2019;Reilly &#xc9;J, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. Apr 30 2019;92(18):e2089&#x2013;e2100. doi:10.1212/wnl.0000000000007401</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000007401</ArticleId><ArticleId IdType="pmc">PMC6512888</ArticleId><ArticleId IdType="pubmed">30926684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration. Sep 2014;15(5&#x2013;6):362&#x2013;70. doi:10.3109/21678421.2014.908311</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.908311</ArticleId><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. Jan 2012;13(1):110&#x2013;8. doi:10.3109/17482968.2011.619197</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.619197</ArticleId><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol J, Jov&#xe9; M, Povedano M, et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021;3(3):fcab143. doi:10.1093/braincomms/fcab143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab143</ArticleId><ArticleId IdType="pmc">PMC8361390</ArticleId><ArticleId IdType="pubmed">34396104</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Annals of neurology. Oct 2002;52(4):448&#x2013;57. doi:10.1002/ana.10312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. Dec 2018;70:51&#x2013;64. doi:10.1016/j.jbior.2018.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2018.09.013</ArticleId><ArticleId IdType="pmc">PMC6251739</ArticleId><ArticleId IdType="pubmed">30287225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P, Donkervoort S, Lone MA, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. Jul 2021;27(7):1197&#x2013;1204. doi:10.1038/s41591-021-01346-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01346-1</ArticleId><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile Acid Physiology. Ann Hepatol. Nov 2017;16(Suppl. 1: s3-105.):s4&#x2013;s14. doi:10.5604/01.3001.0010.5493</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/01.3001.0010.5493</ArticleId><ArticleId IdType="pubmed">29080336</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. The New England journal of medicine. Sep 3 2020;383(10):919&#x2013;930. doi:10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle &amp; nerve. Jan 2021;63(1):31&#x2013;39. doi:10.1002/mus.27091</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry GJ, Rodrigues CM, Aranha MM, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. Jan-Feb 2010;33(1):17&#x2013;21. doi:10.1097/WNF.0b013e3181c47569</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNF.0b013e3181c47569</ArticleId><ArticleId IdType="pubmed">19935406</ArticleId></ArticleIdList></Reference><Reference><Citation>Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. Feb 2012;27(2):200&#x2013;6. doi:10.3346/jkms.2012.27.2.200</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2012.27.2.200</ArticleId><ArticleId IdType="pmc">PMC3271295</ArticleId><ArticleId IdType="pubmed">22323869</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Veyrat-Durebex C, Bocca C, et al. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. Dec 15 2017;7(1):17652. doi:10.1038/s41598-017-17389-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KH, Lin CN, Chen CM, et al. Altered Metabolic Profiles of the Plasma of Patients with Amyotrophic Lateral Sclerosis. Biomedicines. Dec 18 2021;9(12)doi:10.3390/biomedicines9121944</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121944</ArticleId><ArticleId IdType="pmc">PMC8699018</ArticleId><ArticleId IdType="pubmed">34944760</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eunen K, Simons SM, Gerding A, et al. Biochemical competition makes fatty-acid &#x3b2;-oxidation vulnerable to substrate overload. PLoS Comput Biol. 2013;9(8):e1003186. doi:10.1371/journal.pcbi.1003186</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003186</ArticleId><ArticleId IdType="pmc">PMC3744394</ArticleId><ArticleId IdType="pubmed">23966849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I, Kazamel M, McPherson T, et al. Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy x-ray absorptiometry in a prospective study. PLoS One. 2021;16(5):e0251087. doi:10.1371/journal.pone.0251087</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251087</ArticleId><ArticleId IdType="pmc">PMC8101939</ArticleId><ArticleId IdType="pubmed">33956876</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Ou R, Wei Q, Shang H. Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging. Jun 2021;102:211 e1&#x2013;211 e9. doi:10.1016/j.neurobiolaging.2021.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.01.023</ArticleId><ArticleId IdType="pubmed">33640203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Huang T, Fan D. Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. Annals of neurology. Mar 2020;87(3):434&#x2013;441. doi:10.1002/ana.25671</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25671</ArticleId><ArticleId IdType="pubmed">31916305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernihough A, McGovern ME. Physical stature decline and the health status of the elderly population in England. Econ Hum Biol. Jan 2015;16:30&#x2013;44. doi:10.1016/j.ehb.2013.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehb.2013.12.010</ArticleId><ArticleId IdType="pmc">PMC4103973</ArticleId><ArticleId IdType="pubmed">24508050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>